Pei-Ying Wu
Papers
1
Total Citations
10
H-Index
1
About
Dr. Pei-Ying Wu is a clinical researcher specializing in gynecologic oncology, with a particular focus on ovarian, tubal, and peritoneal cancers. Her work bridges the gap between clinical trial evidence and real-world patient outcomes, especially for Asian populations. Her most notable contribution is the landmark ROBOT study ("Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy"), which analyzed eight years of clinical experience to determine the long-term prognostic impacts and adverse effects of bevacizumab (BEV) in combination with chemotherapy. This study, cited 10 times, provides critical real-world evidence on treatment efficacy and safety, helping to refine therapeutic strategies beyond controlled trial settings. Dr. Wu’s research is instrumental in understanding how targeted therapies perform in diverse, everyday clinical practice, offering valuable insights for oncologists treating Asian patients with these challenging malignancies.
Research Focus
Key Achievements
Top Papers
- 1